Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AEROVATE THERAPEUTICS, INC.

(AVTE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/15/2021 10/18/2021 10/19/2021 10/20/2021 10/21/2021 Date
14.13(c) 16.89(c) 14.27(c) 13.3(c) 13.01(c) Last
106 828 2 219 837 211 338 198 620 96 091 Volume
-18.65% +19.53% -15.51% -6.80% -2.18% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -22,2 M - -
Net cash position 2021 122 M - -
P/E ratio 2021 -8,50x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -28,6 M - -
Net cash position 2022 102 M - -
P/E ratio 2022 -11,5x
Yield 2022 -
Capitalization 318 M 318 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 8
Free-Float 100,0%
More Financials
Company
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The Company's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the... 
More about the company
All news about AEROVATE THERAPEUTICS, INC.
09/20AEROVATE THERAPEUTICS : Slumps After Addition to Russell 2000 Index
MT
09/20AEROVATE THERAPEUTICS, INC.(NASDAQGM : AVTE) added to S&P TMI Index
CI
09/17AEROVATE THERAPEUTICS : to Join Russell 2000 Index
MT
09/17Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index
GL
08/24AEROVATE THERAPEUTICS : Wedbush Sees Aerovate's Drug Candidate AV-101 Generating Annual Re..
MT
08/16AEROVATE THERAPEUTICS : Announces Second Quarter 2021 Financial Results (Form 8-K)
PU
08/16AEROVATE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/16AEROVATE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
08/16AEROVATE THERAPEUTICS : Announces Second Quarter 2021 Financial Results
AQ
08/16Aerovate Therapeutics, Inc. Announces Consolidated Financial Results for the Quarter an..
CI
08/12AEROVATE THERAPEUTICS : FOR PREMISES LOCATED AT (Form 8-K)
PU
08/12AEROVATE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Di..
AQ
07/26AEROVATE THERAPEUTICS : Evercore ISI Group Initiates Aerovate Therapeutics at Outperform R..
MT
07/26AEROVATE THERAPEUTICS : Jefferies Starts Aerovate Therapeutics at Buy With $21 Price Targe..
MT
07/26AEROVATE THERAPEUTICS : Cowen Initiates Coverage on Aerovate Therapeutics With Outperform ..
MT
More news
News in other languages on AEROVATE THERAPEUTICS, INC.
09/20Aerovate Therapeutics dégringole après son entrée dans l'indice Russell 2000
More news
Analyst Recommendations on AEROVATE THERAPEUTICS, INC.
More recommendations
Chart AEROVATE THERAPEUTICS, INC.
Duration : Period :
Aerovate Therapeutics, Inc. Technical Analysis Chart | AVTE | US0080641071 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 13,01 $
Average target price 24,67 $
Spread / Average Target 89,6%
EPS Revisions
Managers and Directors
Timothy P. Noyes Chief Executive Officer & Director
Benjamin T. Dake President, Chief Operating Officer & Secretary
George A. Eldridge CFO, Treasurer & Principal Accounting Officer
Mark T. Iwicki Chairman
Hunter Gillies Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AEROVATE THERAPEUTICS, INC.0.00%318
MODERNA, INC.225.04%134 418
LONZA GROUP AG29.18%59 339
IQVIA HOLDINGS INC.42.23%48 194
SEAGEN INC.-0.71%31 811
CELLTRION, INC.-39.42%25 446